NCT/Study#

BST004

A Phase 2, Open Label, Single Arm, Multi‐Center Study to Assess the Efficacy and Safety of BST‐236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome?

A Phase 2, Open Label, Single Arm, Multi‐Center Study to Assess the Efficacy and Safety of BST‐236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome?

DISEASE GROUP:
Leukemia
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: